| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Actionable
answers
Guiding diagnosis, prognosis, and therapy options
Our comprehensive test menu includes testing to aid in providing both diagnostic and prognostic information, and in treatment selection across the full spectrum of malignancies. Each assay is developed and validated in collaboration with Mayo Clinic oncologists, pathologists, and laboratorians. Through our clinical experience and expertise, we strive to provide testing options that improve patient care, increase efficiency, and reduce costs.
Stay up-to-date on the latest discoveries and test launches. Sign up for our monthly oncology newsletter.
Additional test offerings
Results that matter
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
100+
genetic tests developed for solid tumors
9
areas of specialized oncology testing
20+
board-certified geneticists
specializing in molecular and
cytogenetic diagnostic testing
24/7
support from Mayo Clinic physicians and scientists
Diagnostic, prognostic, and predictive testing
Our comprehensive menu offers testing to provide diagnostic and prognostic information and helps guide treatment selection across the full spectrum of malignancies. Our tumor-specific panels only include genes that are clinically proven to impact patient outcomes. This eliminates confusing results, decreases the cost of testing, and leads to better patient care.
Integration of clinical care, pathology, genetics, and bioinformatics
We take the lead in designing and optimizing testing to guide patient care based on specific tumors. Our experience with clinical care is integrated with our expertise in pathology, genetics, and bioinformatics to direct which genes are selected for each panel and how these panels are used in a clinical setting.
Providing answers,
not just results
Genetic testing is about more than just determining whether a mutation is present or not. We take complex genetic results and turn them into clinically actionable answers. Our clinicians, laboratorians, and genetic counselors are available 24/7 to provide expertise and consultative support, eliminating the guesswork from results interpretation.
Webinar: Practical Aspects and Pitfalls of the Molecular Diagnosis of Brain Tumors
This “Specialty Testing” webinar will address practical aspects and pitfalls in the molecular diagnosis of brain tumors. All molecular testing platforms have factors that impact testing in the pre-analytical, analytical, and post-analytical phases. These factors will be discussed during the presentation and highlighted through clinical cases to illustrate the pitfalls in brain tumor molecular diagnosis encountered in the clinical practice at Mayo Clinic.
The Latest
With the rise of next generation sequencing (NGS) technology, multigene panel testing is expanding so rapidly that clinical practice is racing to keep pace. And questions within genetic tests have expanded along with it, making definitive answers more challenging to come by. Experts in the Genomics Laboratory in Mayo Clinic's Department of Laboratory Medicine and Pathology work to explain this often misunderstood technology.
This "Specialty Testing" webinar will address practical aspects and pitfalls in the molecular diagnosis of brain tumors.
In this month’s “Hot Topic,” Anja Roden, M.D., will discuss the role of PD-L1 interaction in the immune system, challenges with PD-L1 testing, and current PD-L1 testing in Non-Small Cell Lung Carcinoma (NSCLC).
William Sukov, M.D., provides an overview of the MDM2 gene amplification assay — a test that looks for amplification of the MDM2 gene region on chromosome 12q. He reviews when this test should be ordered, how it compares to other test options, and how its results can affect patient care.
Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) is an autosomal dominant hereditary cancer syndrome associated with germline mutations in the mismatch repair genes, MLH1, MSH2, MSH6, and PMS2. Deletions within the 3' end of the EPCAM gene, which lead to inactivation of the MSH2 promotor, have also been associated with Lynch syndrome.